Active Not Recruiting PHASE1 INTERVENTIONAL 2-arm NCT06036121

A Study of ADRX-0706 in Select Advanced Solid Tumors

A Phase 1a/b Study of ADRX-0706 in Subjects With Select Advanced Solid Tumors

Sponsor: Adcentrx Therapeutics

Conditions Cervical Cancer Solid Tumors Triple Negative Breast Cancer (TNBC) Urothelial Cancer

Interventions ADRX-0706

Updated 8 times since 2023 Last updated: Aug 13, 2025 Started: Sep 26, 2023 Primary completion: Sep 30, 2025 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Cervical Cancer and Solid Tumors, this trial is ongoing. The trial is conducted by Adcentrx Therapeutics and has accumulated 8 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Jan 2025 — Sep 2025 [monthly]

Recruiting PHASE1
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Mar 2024 — Jul 2024 [monthly]

Recruiting PHASE1

▶ Show 3 earlier versions

Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE1
Nov 2023 — Feb 2024 [monthly]

Recruiting PHASE1
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE1

First recorded

Sep 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Adcentrx Therapeutics

Data source: Adcentrx Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Detroit, United States , Fujian, China , Grand Rapids, United States , Guangzhou, China , Hilliard, United States , Houston, United States , Hunan, China , Jinan, China , Los Angeles, United States and 8 more locations